Prostate Cancer

Does Epigenetic Therapy With Panobinostat Reduce CRPC Bicalutamide Resistance?

Does Epigenetic Therapy With Panobinostat Reduce CRPC Bicalutamide Resistance?

By

Panobinostat plus bicalutamide increased radiographic progression-free survival in patients with CRPC resistant to second-line antiandrogen therapy.

Men With Prostate Cancer Willing to Accept Worse Survival Odds to Improve QoL

Men With Prostate Cancer Willing to Accept Worse Survival Odds to Improve QoL

By

Trade-offs should be carefully considered, as data have indicated that many QoL factors eventually even out.

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

By

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

The Patient Behind the EHR: Oncologists Only See Half the Picture

The Patient Behind the EHR: Oncologists Only See Half the Picture

By

Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.

Prognostic Model for Survival in Metastatic Prostate Cancer

Prognostic Model for Survival in Metastatic Prostate Cancer

By

Utilizing data from the PREVAIL dataset, researchers developed mathematical models that can provide prognostic information for men being treated with enzalutamide for chemotherapy-naïve metastatic castration-resistant prostate cancer.

Anticarcinogenic Activity of Fish Oil Explored in Study

Anticarcinogenic Activity of Fish Oil Explored in Study

By

Omega-3 fatty acids found in fish oil act through a host receptor, GPR120, to confer anti-prostate cancer effects. Additional studies are underway.

Radiotherapy Did Not Improve Survival in All Patients With Metastatic Prostate Cancer

Radiotherapy Did Not Improve Survival in All Patients With Metastatic Prostate Cancer

By

Radiotherapy may improve survival among men with low metastatic burden, but not in all patients with metastatic prostate cancer.

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

By

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

By

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets

Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets

By

The regimen did not improve survival and increased bone fractures.

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

By

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer

Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer

By

Findings from the SPARTAN trial show that HRQoL is not diminished by adding apalutamide to androgen deprivation therapy in men with asymptomatic, nonmetastatic CRPC.

Native Puerto Ricans Are at Increased Risk for Certain Cancers

Native Puerto Ricans Are at Increased Risk for Certain Cancers

By

Cancer occurrence in island Puerto Ricans and Puerto Ricans living in the continental US and Hawaii differ considerably.

Bladder Cancer Risk Higher With Radiation Therapy for Prostate Cancer

Bladder Cancer Risk Higher With Radiation Therapy for Prostate Cancer

By

In a recently published study, external beam radiation therapy for localized prostate cancer was associated with a 35% increased risk of bladder cancer compared with radical prostatectomy.

Comparison of Multimodal Approaches in High-Risk Prostate Cancer

Comparison of Multimodal Approaches in High-Risk Prostate Cancer

By

Men treated with radical prostatectomy plus radiotherapy for locally or regionally advanced prostate cancer had improved survival but worse adverse events.

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

By

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

By

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

High Mutation Load Seen in the High-Risk Prostate Tumors of African Men

High Mutation Load Seen in the High-Risk Prostate Tumors of African Men

By

Differences in TMB between African and European patients show that "racial mutational disparity is not a technical or computational artifact," according to authors.

Prostate Cancer Drug Resistance Mediated by Epigenetic Changes

Prostate Cancer Drug Resistance Mediated by Epigenetic Changes

By

Epigenetic changes in the tumor microenvironment may explain why prostate cancer patients develop resistance to androgen signaling deprivation therapy.

Study Zeroes in on Cause of Castration-Resistant Prostate Cancer

Study Zeroes in on Cause of Castration-Resistant Prostate Cancer

By

Some prostate cancer cells lack androgen receptors, and they proliferate faster than those that express androgen receptors under androgen-deficient conditions.

Genetic Counseling Recommended for Advanced Prostate Cancer

Genetic Counseling Recommended for Advanced Prostate Cancer

By

A new white paper emphasizes the benefits of germline testing.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Heavy Alcohol Intake in Early Life May Significantly Increase Odds of High-Grade Prostate Cancer

Heavy Alcohol Intake in Early Life May Significantly Increase Odds of High-Grade Prostate Cancer

By

Recent analyses suggest that lifetime intake and early-life alcohol use may significantly contribute to the development of high-grade prostate cancer.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

IL-23 Drives Castration-Resistant Prostate Cancer

IL-23 Drives Castration-Resistant Prostate Cancer

By

A growing body of evidence points to infiltrating myeloid-derived suppressor cells as key players in tumor progression and acquired treatment resistance.

SBRT Appears Effective for Oligometastatic Prostate Cancer

SBRT Appears Effective for Oligometastatic Prostate Cancer

By

Stereotactic body radiation therapy achieves good local control of metastases in patients with recurrent prostate cancer following primary treatment.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

By

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

First-Line Enzalutamide May Confer a Survival Benefit for Metastatic Castration-Resistant Prostate Cancer

First-Line Enzalutamide May Confer a Survival Benefit for Metastatic Castration-Resistant Prostate Cancer

By

Patients may benefit from earlier lines of enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs